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Data on correlations of plasma apoE with levels of lipids and
lipoproteins stratiﬁed by APOE genotypes as well as data exploring
the association between plasma levels of apoE and risk of ischemic
heart disease (IHD) are wanted.
The present data on 91,695 individuals from the general
population provides correlations between plasma levels of apoE
and lipids and lipoproteins for the three APOE genotypes ε33, ε44
and ε22, representing each of the three apoE isoforms. Further,
data on extreme groups of plasma apoE (highest 5%) versus lower
levels of apoE at enrollment explores risk of IHD and myocardial
infarction (MI) and is given as hazard ratios. In addition, IHD
and MI as a function of apoE/high-density lipoprotein (HDL) cho-
lesterol ratio, as well as data on lipids, lipoproteins andvier Inc. This is an open access article under the CC BY license
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K.L. Rasmussen et al. / Data in Brief 6 (2016) 923–932924apolipoproteins are given as hazard ratios. Data is stratiﬁed by
gender and presented for the Copenhagen General Population
Study and the Copenhagen City Heart Study combined.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Clinical Research – Epidemiology, Biomarkers, Nutrition
ore speciﬁc sub-
ject areaEpidemiology, genetics, biomarkers, ischemic heart disease, myocardial infarc-
tion, apolipoprotein E, APOE, triglycerides, HDL.ype of data Table, Figures.
ow data was
acquiredThe Copenhagen General Population Study and the Copenhagen City Heart Study
are two large prospective studies of the general population.ata format Analyzed data.
xperimental
factorsData on participants in two similar studies of the Danish general population:
The Copenhagen General Population Study and The Copenhagen City Heart
Study, with altogether 91,695 participants, of whom 4642 developed IHD.xperimental
featuresData was obtained from a questionnaire, a physical examination, and from
blood samples including DNA extraction. Plasma levels of apolipoprotein E, APOE
genotypes as well as lipids and lipoproteins were measured.ata source
locationCopenhagen, Denmark.ata accessibility Data is within this article.Value of the data Data on correlations between plasma levels of apolipoprotein E (apoE) and lipids and lipoproteins
for the three APOE genotypes, ε33, ε44 and ε22, provides value as isoform speciﬁc references.
 These robust human isoform speciﬁc data may stimulate experimental research on structure–
function relationships.
 The data suggests that triglyceride-mediated pathways may explain the associations between
plasma levels of apoE and ischemic heart disease (IHD), and may stimulate the scientiﬁc society to
explore triglyceride metabolism further.
1. Data
The present data in 91,695 individuals from the general population provides correlations between
plasma levels of apoE and lipids and lipoproteins for the three APOE genotypes ε33, ε44 and ε22,
representing each of the three apoE isoforms. Further, data in the form of hazard ratios for extreme
groups of plasma apoE (highest 5%), tertiles of apoE, tertiles of apoE/HDL cholesterol ratio as well as
tertiles of lipids, lipoproteins and apolipoproteins for risk of IHD and myocardial infarction (MI) is
given. Additionally, data on characteristics of participants by apoE tertile is presented. Data is given as
analyzed data (Figs. 1–8 and Table 1).2. Experimental design, materials and methods
We used data from two similar studies of the Danish general population, the Copenhagen General
Population Study (CGPS) and the Copenhagen City Heart Study (CCHS), with altogether 91,695
Fig. 1. Correlations of lipids, lipoproteins, and apolipoproteins with plasma levels of apolipoprotein E in ε33 individuals in men
(left panel) and women (right panel). Values are median and interquartile range. ρ¼Spearman's rho correlation coefﬁcient.
p¼probability values for Spearman's rank correlation coefﬁcient for the continuous values of lipids, lipoproteins, and apoli-
poproteins. ε33¼APOE ε33 genotype.
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Fig. 2. Correlations of lipids, lipoproteins, and apolipoproteins with plasma levels of apolipoprotein E in ε44 individuals in men
(left panel) and women (right panel). Values are median and interquartile ranges. ρ¼Spearman's rho correlation coefﬁcient.
p¼probability values for Spearman's rank correlation coefﬁcient for the continuous values of lipids, lipoproteins, and apoli-
poproteins. ε44¼APOE ε44 genotype.
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Fig. 3. Correlations of lipids, lipoproteins, and apolipoproteins with plasma levels of apolipoprotein E in ε22 individuals in men
(left panel) and women (right panel). Values are median and interquartile range. For groups with Nr2 values are given for
each individual separately (▲). ρ¼Spearman's rho correlation coefﬁcient. p¼probability values for Spearman's rank correlation
coefﬁcient for the continuous values of lipids, lipoproteins, and apolipoproteins. ε22¼APOE ε22 genotype.
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Fig. 5. Risk of ischemic heart disease (left panel) and myocardial infarction (right panel) as a function of plasma levels of
apolipoprotein E in tertiles, in men (upper panel) and women (lower panel) with adjustment including HDL cholesterol. Hazard
ratios were multifactorially adjusted for age, body mass index, hypertension, diabetes mellitus, smoking, alcohol consumption,
physical inactivity, menopausal status and hormonal replacement therapy (only women), lipid-lowering therapy, education,
and HDL cholesterol, and were stratiﬁed by sex. Tertiles of HDL cholesterol were used for adjustment for HDL cholesterol. We
tested highest and middle versus lowest tertile of apoE. CI¼conﬁdence interval. HDL¼high-density lipoprotein.
Fig. 4. Risk of ischemic heart disease (two left panels) and myocardial infarction (two right panels) as a function of plasma
levels of apolipoprotein E in extreme groups in men (upper panels) and women (lower panels). Hazard ratios were multi-
factorially adjusted for age, body mass index, hypertension, diabetes mellitus, smoking, alcohol consumption, physical inac-
tivity, menopausal status and hormonal replacement therapy (only women), lipid-lowering therapy, and education, and were
stratiﬁed by sex. apoE¼apolipoprotein. CI¼conﬁdence interval.
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Fig. 6. Risk of ischemic heart disease (two left panels) and myocardial infarction (two right panels) as a function of apoE/HDL
cholesterol in tertiles, in men (upper panel) and women (lower panel). Hazard ratios were multifactorially adjusted for age,
body mass index, hypertension, diabetes mellitus, smoking, alcohol consumption, physical inactivity, menopausal status and
hormonal replacement therapy (only women), lipid-lowering therapy, and education, and were stratiﬁed by sex. Further
adjustment included triglycerides in tertiles. apoE/HDLcholesterol¼ratio of apolipoprotein E relative to high-density lipo-
protein cholesterol. We tested highest and middle versus lowest tertile. CI¼conﬁdence interval.
Fig. 7. Risk of ischemic heart disease (two left panels) and myocardial infarction (two right panels) as a function of apoE/HDL
cholesterol in tertiles, in men (upper panel) and women (lower panel) in APOE genotype adjusted and ε33 stratiﬁed analyses.
Hazard ratios were multifactorially adjusted for age, body mass index, hypertension, diabetes mellitus, smoking, alcohol
consumption, physical inactivity, menopausal status and hormonal replacement therapy (only women), lipid-lowering therapy,
and education, and were stratiﬁed by sex. Analyses were further adjusted for APOE genotype or analyzed in individuals with
ε33 APOE genotype only. We tested highest and middle versus lowest tertile. apoE/HDL cholesterol¼ratio of apolipoprotein E
relative to high-density lipoprotein cholesterol. CI¼conﬁdence interval. ε33¼APOE ε33 genotype.
K.L. Rasmussen et al. / Data in Brief 6 (2016) 923–932 929participants, of whom 4642 developed IHD [1–3]. Data was obtained from a questionnaire, a physical
examination, and from blood samples including DNA extraction [1–3]. The CGPS is a prospective
study of the Danish general population initiated in 2003 with ongoing enrollment, whereas the CCHS
is a prospective study of the Danish general population initiated in 1976–78 with follow-up exam-
inations in 1981–83, 1991–94, and 2001–03. Studies were approved by institutional review boards
and Danish ethical committees, and were conducted according to the Declaration of Helsinki. Written
informed consent was obtained from participants. All participants were white and of Danish descent.
There was no overlap of individuals between the CGPS and the CCHS.
Fig. 8. Risk of ischemic heart disease (left panel) and myocardial infarction (right panel) as a function of lipids, lipoproteins,
and apolipoproteins. Hazard ratios were multifactorially adjusted for age, body mass index, hypertension, diabetes mellitus,
smoking, alcohol consumption, physical inactivity, menopausal status and hormonal replacement therapy (only women), lipid-
lowering therapy, and education, and were stratiﬁed by sex. HDL¼high-density lipoprotein. LDL¼ low-density lipoprotein.
CI¼conﬁdence interval.
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Table 1
Characteristics of participants by apolipoprotein E tertile.
Men Women
Lowest
tertile
Middle
tertile
Highest
tertile
Lowest
tertile
Middle
tertile
Highest
tertile
No. of individuals (%) 13,369 (33) 13,368 (33) 13,357 (33) 17,207 (33) 17,203 (33) 17,191 (33)
Age (years) 55.970.1 57.270.1a 57.770.1a 51.870.1 57.770.1a 60.970.09a
Apolipoprotein E (mg/dL) 3.070.004 4.070.002a 5.770.01a 3.170.004 4.270.002a 6.070.01a
Total cholesterol (mmol/L) 5.170.008 5.770.008a 6.170.01a 5.270.007 5.870.008a 6.270.009a
HDL cholesterol (mmol/L) 1.470.003 1.4270.004 1.470.004a 1.770.003 1.870.004a 1.970.004a
Triglycerides (mmol/L)c 1.370.01 1.670.01a 2.270,02a 1.170.01 1.370.01a 1.570.01a
LDL cholesterol (mmol/L) 3.070.007 3.470.008a 3.670.009a 3.070.006 3.470.007a 3.670.008a
Apolipoprotein B (mg/dL) 97.370.2 114.570.2a 134.170.4a 91.670.2 106.070.2a 116.170.3a
Apolipoprotein A1 (mg/dL) 142.970.2 148.970.2a 156.270.2a 159.870.2 166.870.2a 178.270.2a
Body mass index (kg/m2) 25.870.03 26.770.03a 27.670.03a 24.570.03 25.770.03a 26.570.04a
Hypertension (%) 7809 (58) 8698 (65) 9493 (71)a 6941 (40) 9267 (54) 10,719 (62)a
Diabetes mellitus (%) 761 (6) 484 (4) 548 (4)a 442 (3) 467 (3) 502 (3)
Smoking (%) 3204 (24) 3057 (23) 3146 (24) 3764 (22) 3647 (21) 3432 (20)a
Alcohol consumption (%) 2438 (18) 2790 (21) 3210 (24)a 2162 (13) 2593 (15) 2773 (16)a
Physical inactivity (%) 5585 (42) 6091 (46) 6646 (50)a 9041 (53) 9557 (56) 9931 (58)a
Postmenopausal (%)d – – – 8320 (48) 11842 (69) 13,821 (80)a
Hormonal replacement therapy
(%)d
– – – 1935 (11) 1791 (10) 1768 (10)b
Lipid-lowering therapy (%) 1604 (12) 1115 (8) 730 (5)a 1380 (8) 1402 (8) 1074 (6)a
Education o8 years (%) 1612 (12) 1713 (13) 1796 (13)b 1370 (8) 2224 (13) 2711 (16)a
Values are mean (7standard error of the mean) or percent, and are from the day of enrollment (2003 and onwards for the
Copenhagen General Population Study and 1991–94 or 2001–03 for the Copenhagen City Heart Study). Missing data on
categorical and continuous covariates (o1.0%) were imputed from age and population using multiple imputation. Hyper-
tension was use of anti-hypertensive medication and/or a systolic blood pressure of 140 mm Hg or greater, and/or a diastolic
blood pressure of 90 mm Hg or greater. Diabetes mellitus was self-reported disease, use of insulin or oral hypoglycaemic
agents, and/or non-fasting plasma glucose levels of more than 11 mmol/L (4198 mg/dL). Smoking was current smoking.
Alcohol consumption was 414/21 units per week for women/men (1 unit¼12 g alcohol, equivalent to one glass of wine or one
beer (33 cL)). Physical inactivity was r4 hours per week of light physical activity in leisure time. Women reported menopausal
status and use of hormonal replacement therapy. Lipid-lowering therapy was primarily statins (yes/no), and education was o8
years of education apo0.001 and bpo0.05 by Student's t-test for lowest apolipoprotein E tertile versus middle tertile and for
lowest tertile versus highest tertile, respectively, or Pearson's χ2-test for a 23 table with the signiﬁcance level for the overall
23 table indicated in the columns with the highest tertile. cGeometric mean7standard error of the mean for unimputed
triglyceride levels is shown. dIn women only.
K.L. Rasmussen et al. / Data in Brief 6 (2016) 923–932 931Information on diagnoses of IHD (World Health Organization International Classiﬁcation of Dis-
eases (ICD), 8th version, ICD8: 410-414, 10th version ICD10:I20-I25) was collected from the National
Danish Patient Registry and the National Danish Causes of Death Registry. IHD was ICD8 410-414; and
ICD10 I20-I25; MI constitutes a subgroup (ICD8 410 and ICD10 I21-I22).
Follow-up time began at the time of blood sampling (2003 and onwards for CGPS and 1991–94 or
2001–03 for CCHS). Follow-up ended at occurrence of event, death, emigration, or on April 10th, 2013
(last update of the registry), whichever came ﬁrst. Median follow-up was 5 years (range 0–22 years)
with no individuals lost to follow-up.
Biochemical and genetic analyses were similar to analyses provided by Rasmussen et al. [4,5].
For the statistical analyses we used Stata/S.E. version 12.0 (Stata Corp., College Station, Texas, USA).
P-valueso0.0001 are given as powers of 10. Student's t-test and Pearson's χ2 -test were used in
comparisons of continuous and categorical variables, respectively. Spearman's rank correlation was
used for the correlation of continuous values of lipids, lipoproteins, and apolipoproteins with con-
tinuous values of apoE, stratiﬁed by the homozygote APOE genotypes, ε33, ε44 and ε22, representing
each of the three apoE isoforms. Missing data on categorical and continuous covariates (o1.0%) were
imputed from age, sex and population using multiple imputation with ten imputations. Multinomial
logistic regression was applied for categorical variables and linear regression for continuous variables,
K.L. Rasmussen et al. / Data in Brief 6 (2016) 923–932932and was performed using the “mi impute mlogit” and “mi impute chained (regress)” commands
in Stata.
Cox proportional hazards regression models estimated hazard ratios for MI and IHD as a function
of extreme groups and tertiles of plasma levels of apoE, tertiles of apoE/HDL cholesterol ratios, and
tertiles of lipids, lipoproteins, and apolipoproteins. In the Cox models we adjusted for age (automatic
adjustment as age is the time scale) and known risk factors as detailed in legend to Table 1. Further
adjustment included adjustment for triglycerides in tertiles, HDL cholesterol in tertiles or APOE
genotype. Further ε33 stratiﬁed analyses for apoE/HDL cholesterol ratios in tertiles were performed.
As gender and apoE levels interacted in predicting IHD (p¼0.04), the analyses were performed
separately for each gender, and data is presented stratiﬁed by gender. Data is presented for the CGPS
and the CCHS combined.Acknowledgments
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